Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity.
CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease.
A team of researchers at Boston University and Stanford University School of Medicine has developed a new model to study the motion patterns of bacteria in real time and to determine how these motions relate to communication within a bacterial colony.
Things can go downhill fast when a patient has sepsis, a life-threatening condition in which bacteria or fungi multiply in a patient's blood -- often too fast for antibiotics to help. A new device inspired by the human spleen and developed by a team at Harvard's Wyss Institute for Biologically Inspired Engineering may radically transform the way doctors treat sepsis.
Dr. Hong Liang's research on how gold nanoparticles can destroy superbacteria in the human body such as Escheria coli and drug-resistant Staphococcus aureus was featured on Popular Mechanics. Liang is a professor in the Department of Mechanical Engineering at Texas A&M University.
Northwestern Medicine® scientists have discovered a novel cause of glaucoma in an animal model, and related to their findings, are now developing an eye drop aimed at curing the disease. They believe their findings will be important to human glaucoma.
Senesco Technologies, Inc., a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc.
The newly merged SUNY College of Nanoscale Science and Engineering (CNSE)/SUNY Institute of Technology (SUNYIT) institution today announced the National Institute of Environmental Health Sciences has awarded a $1.65 million grant to further research conducted by nanobioscience professor Dr. Thomas Begley that identifies signals which cancer cells use to respond to their environment.
Working with a team of scientists from the Technical University of Munich (TU Munich), Brandeis University, and Leiden University in the Netherlands, M. Cristina Marchetti and Mark Bowick, professors in the Soft Matter Program in the College of Arts and Sciences, have engineered and studied “active vesicles." These purely synthetic, molecularly thin sacs are capable of transforming energy, injected at the microscopic level, into organized, self-sustained motion.
Reportlinker.com announces that a new market research report is available in its catalogue: Nanoparticles in Biotechnology, Drug Development and Drug Delivery
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.